Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $110


Benzinga | Aug 4, 2021 09:18AM EDT

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $110

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $116 to $110.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC